Abstract: Objective To explore the expression of peroxiredoxin 1（Prdx1） protein in gastric cancer and determine the relationship of its expression with clinical features and prognosis. Methods Tissue microarray blocks containing gastric cancer tissues and adjacent non-cancerous tissues from 120 patients were constructed. Expression of Prdx1 in gastric cancer tissues and adjacent non-cancerous tissues were analyzed using immunohistochemical study. The relationship between the expression of Prdx1 and clinicopathological characteristics were analyzed as well as the overall survival（OS）.
Results The positive rates of Prdx1 in tumor and adjacent noncancerous tissues were 58.3％（70／120） and 25.0％（30／120） with significant difference（P=0.001）. Overexpression of Prdx1 was significantly associated with lymph node metastasis（P=0.015）and TNM stage（P=0.006）， but not with age， gender， tumor position， tumor size， differentiation and invasive depth. The median OS of patients with Prdx1 positive expression was 56.0 months， significantly shorter than 81.7months of Prdx1 negative expression（P=0.004）. Multivariate analysis revealed that Prdx1 was an independent prognostic factor in patients of stage Ⅰ／Ⅱ. Conclusion Prdx1 expression significantly increases in gastric cancer， suggesting the potential role of Prdx1 in cancer development and progression. Prdx1 expression can be used to predict patients' outcome of gastric cancer.